Boston Scientific (NYSE:BSX), a global medical device maker focused on interventional cardiology and specialty devices, closed at $42.44, down 5.81%. Investors are focused on the cyberattack's lingering disruption and the company's lower fourth-quarter and full-year guidance. Trading volume reached 66.8M shares, coming in about 234% above its three-month average of 20.0M shares. S&P 500 (SNPINDEX:^GSPC) closed at 7,744, up 0.28%, while the Nasdaq Composite (NASDAQINDEX:^IXIC) finished at 26,550, up 0.27%. In the medical devices sector, Medtronic (NYSE:MDT) closed at $94.82, up 0.93%, and Abbott Laboratories (NYSE:ABT) closed at $102.67, down 0.42%, after fresh outlook pressure kept the group in focus. Boston Scientific guided for 3% to 5% sales growth and $0.80 to $0.82 in adjusted EPS for Q3, and came up shy of both figures today, delivering a 1.5% sales increase and $0.73 in adjusted EPS. Management blamed an eight-day disruption from a cyberattack as the primary culprit, estimating it cost the company 300 basis points in sales growth and $0.07 in adjusted EPS.
CryptoAlerta — análise de criptomoedas e mercado em tempo real